Molecule Mechanics: Animated Peptide Explainers
Molecule Mechanics is a YouTube series of animated videos. Each one shows what a peptide drug does inside the body, step by step. Every episode is for learning only, and each one names the sources behind its facts.
The channel explains how a molecule works, where it came from and what the research has found so far. No episode picks a medicine for you, suggests an amount, or points to a seller. Until Molecule Mechanics has a website of its own, Peptides Vietnam hosts the written page for each episode. This page lists them all.
Molecule Mechanics episodes, newest first
Each written page adds answers to common questions and a source list you can check for yourself. Once an episode is public on YouTube, its page also carries the video, the chapter times and the full transcript.
Episode 12 · written guide · video on YouTube from 17 November 2026
Octreotide (Sandostatin): How the Somatostatin Copy Works
Octreotide is not a weight drug. This episode follows the growth hormone brake somatostatin from sheep brains to a Nobel Prize, then shows how chemists cut it from 14 units to 8, flipped two of them and closed a ring so it lasts hours, and which of its five receptors the copy still grips.
Episode 11 · written guide · video on YouTube from 16 November 2026
Tymlos (Abaloparatide): How It Works and Differs From Forteo
Tymlos turns the same bone receptor as Forteo, yet it is patterned on PTHrP, a hormone pulled from lung cancer cells in 1987. This episode covers the two receptor shapes, what the ACTIVE trial could and could not compare, the rat finding and the 2022 approval in men.
Episode 10 · written guide · video on YouTube from 15 November 2026
Forteo (Teriparatide): How It Builds Bone in Osteoporosis
Forteo is a bone drug, not a weight drug. This episode shows why the same hormone that wears bone down when it stays high builds bone when it arrives as a short pulse, then follows its fracture trial, the rat finding that stopped that trial early, and the human data that took the boxed warning off in 2020.
Episode 9 · written guide · video on YouTube from 14 November 2026
Saxenda vs Wegovy: How Liraglutide and Semaglutide Differ
Two GLP-1 copies from one company, cut two ways. This episode shows why liraglutide is half gone in about 13 hours and semaglutide in about a week, what the STEP 8 head to head trial found, and where brands and generics stand in 2026.
Episode 8 · written guide · video on YouTube from 13 November 2026
Imcivree (Setmelanotide): How the MC4R Drug Works
Imcivree is not a GLP-1 drug. This episode runs the brain relay that turns a meal into fullness, from leptin to MC4R, and shows what breaks in each rare condition it is approved for. Then it reads the trials, says which had no placebo group, and explains why a weaker push on MC1R turns skin darker.
Episode 7 · written guide · video on YouTube from 12 November 2026
Exenatide (Byetta): How the Gila Monster GLP-1 Works
The first GLP-1 drug was copied from a lizard. This episode shows how one glycine lets exenatide slip past the enzyme that cuts our own GLP-1, how John Eng found it in 1992, and why no US exenatide product is on sale today.
Episode 6 · written guide · video on YouTube from 11 November 2026
Trulicity (Dulaglutide): How It Works for Type 2 Diabetes
Trulicity hangs two GLP-1 keys on the stem of a human antibody. The episode shows its three parts, why that bulk keeps it working for days, and what it does in the pancreas. Then it reads the REWIND heart trial, the SURPASS-CVOT match against tirzepatide, and the label warnings.
Episode 5 · written guide · video on YouTube from 10 November 2026
Semaglutide vs Tirzepatide for Weight Loss: How They Differ
One molecule fits the GLP-1 lock and the other fits GIP and GLP-1. This episode sorts the seven US brand names and reads the two head-to-head trials, quitters included.
Episode 4 · 5:52 · uploaded 8 November 2026
Foundayo (Orforglipron) for Weight Loss: How It Works
Foundayo is a GLP-1 pill with no peptide in it at all. The episode shows how so small a molecule reaches the blood with no helper, where it docks on the human receptor, and why it ignores the mouse version. It ends with the ATTAIN-1 results, the thyroid warning puzzle and where it is approved.
Episode 3 · 6:00 · uploaded 8 November 2026
Oral Semaglutide Tablets: How the Wegovy Pill Works
Most peptide medicines have to be shots, because the gut digests them. This episode follows one semaglutide tablet into the stomach to show how its helper, SNAC, gets a tiny share into the blood. It sorts out Rybelsus, Ozempic tablets and the Wegovy pill, and meets Foundayo, a GLP-1 pill that is no peptide at all.
Episode 2 · 5:27 · uploaded 6 November 2026
Cagrilintide: What It Is and How It Works, Animated
Cagrilintide is a slow, lab-built version of amylin, a hormone from the pancreas that helps you feel full after you eat. The episode shows the four receptors it fits and why it stays in the blood for about a week. It also covers a design idea taken from rat amylin, and why it is still in trials.
Episode 1 · 4:57 · uploaded 5 November 2026
How Does Tirzepatide Work? GIP and GLP-1, Animated
Tirzepatide is the medicine sold as Mounjaro and Zepbound. It acts on the receptors for two gut hormones, GIP and GLP-1, at the same time. The episode follows it to the pancreas, stomach and brain. It also explains the tail it shares with a peptide first found in Gila monster venom.
Sources: Episode 4 on YouTube; Episode 3 on YouTube; Episode 2 on YouTube; Episode 1 on YouTube
How do the drugs in the series so far differ?
They start from different hormones. Tirzepatide is built on GIP, a gut hormone, and is made to switch on both the GIP and the GLP-1 receptors. Cagrilintide is built to act like amylin, a hormone the pancreas lets out along with insulin. So they work through different locks in the body, which is why one company is testing cagrilintide next to a GLP-1 drug. Semaglutide, the drug in episode 3, is a copy of GLP-1 alone, and the episode is about its route in: a tablet instead of a shot. Foundayo, in episode 4, reaches the same GLP-1 lock with no peptide in its build. Chemists made it as a small molecule, so it gets through the gut without a helper.
| Tirzepatide (episode 1) | Cagrilintide (episode 2) | Oral semaglutide (episode 3) | Foundayo (episode 4) | |
|---|---|---|---|---|
| Hormone it is based on | GIP, made in the gut | Amylin, made in the pancreas | GLP-1, made in the gut | None. It is a small molecule, not a copy of a hormone |
| Receptors it acts on | The GIP and GLP-1 receptors | The calcitonin receptor and the three amylin receptors | The GLP-1 receptor | The human GLP-1 receptor |
| US status, November 2026 | US approved: Mounjaro (type 2 diabetes) and Zepbound (weight management) | Not approved. In phase 3 trials, alone and inside CagriSema, which Novo Nordisk filed with the FDA in December 2025 | US approved as tablets: Rybelsus and Ozempic tablets (type 2 diabetes), Wegovy pill (weight) | US approved as Foundayo (weight reduction), April 2026 |
The newest page in the series is octreotide, sold as Sandostatin, a lab-made copy of somatostatin, the body's brake on growth hormone. Retatrutide, which episode 2 named as coming up, is still experimental. It is built to act on three receptors: GIP, GLP-1 and glucagon. ClinicalTrials.gov lists its phase 3 studies, so it is still being tested in people.
Sources: Mounjaro approval record (FDA database); Zepbound approval record (FDA database); Study of how long cagrilintide stays in the body (2026); CagriSema US new drug application, Novo Nordisk news release (December 2025); Novo Nordisk third quarter 2026 financial report; Semaglutide tablet approval records (FDA database, applications 213051 and 218316); FDA announcement approving orforglipron as Foundayo (April 2026); Phase 2 retatrutide weight study (New England Journal of Medicine, 2023); Registered phase 3 retatrutide trials (US trial registry)
Who are these explainers for?
They are for anyone who hears a drug name in the news and wants to know what it actually does inside the body. Students use them to see a mechanism drawn out step by step. Readers use them to come to a doctor visit with better questions. Each page keeps the science in plain words and shows where every claim comes from.
How is every Molecule Mechanics episode made?
Sources first. Each episode lists the sources it used. They include drug labels, papers checked by other scientists, review articles, trial records and protein databases. The written page lists those records at the end of each section. You can open them and read the original.
Education only. The videos and pages describe what studies and labels say. They leave out dose figures, prices and shopping links on purpose. Questions about a medicine are for a licensed clinician who knows your health.
Clear about how it is made. Each video says in its YouTube description that the narrator is an AI voice and that the animation is original. The written pages use plain words. A hard word gets a short meaning next to it. For example, the series pictures a receptor as a lock.
Fixes in the open. If we get something wrong, we fix the page and say so, as set out in our corrections policy. Health facts go through the steps in our medical review policy.
Where can I watch Molecule Mechanics?
Public episodes are free to watch on YouTube, with English captions. New ones are added here soon after they go up, so this page stays a full list of the series.
Open the Molecule Mechanics channel on YouTube
Sources: Molecule Mechanics channel, YouTube
Education only, not medical advice. Molecule Mechanics videos and pages explain published research and drug labels. Talk it over with a licensed clinician before you decide anything about a medicine.



